外周T细胞淋巴瘤-话题@MedSci

#外周T细胞淋巴瘤#

32篇内容 | 2878人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1312226, encodeId=662f131222614, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=98, createdTime=2021-12-04, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312225, encodeId=927e131222589, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, objectType=article, longId=219960, objectId=f2d521996079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d521996079, replyNumber=0, likeNumber=92, createdTime=2021-11-09, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d521996079, moduleTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d521996079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312224, encodeId=5f471312224a2, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=科普贴：外周T细胞淋巴瘤（PTCL）, objectType=article, longId=215397, objectId=3c8321539ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8321539ee2, replyNumber=0, likeNumber=95, createdTime=2021-08-08, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8321539ee2, moduleTitle=科普贴：外周T细胞淋巴瘤（PTCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8321539ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312223, encodeId=e75b131222318, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=94, createdTime=2021-07-14, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312222, encodeId=7e6f131222264, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, objectType=article, longId=213648, objectId=33d021364893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33d021364893, replyNumber=0, likeNumber=69, createdTime=2021-07-04, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33d021364893, moduleTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33d021364893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312221, encodeId=ec12131222126, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, objectType=article, longId=203797, objectId=5552203e971c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5552203e971c, replyNumber=0, likeNumber=131, createdTime=2020-11-28, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5552203e971c, moduleTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5552203e971c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312220, encodeId=b0f71312220a0, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, objectType=article, longId=203701, objectId=4e38203e015a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e38203e015a, replyNumber=0, likeNumber=76, createdTime=2020-11-26, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e38203e015a, moduleTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e38203e015a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312219, encodeId=a8d01312219a8, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, objectType=article, longId=198316, objectId=e83e198316b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e83e198316b3, replyNumber=0, likeNumber=128, createdTime=2020-07-31, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e83e198316b3, moduleTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e83e198316b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312218, encodeId=d2151312218e3, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：两种新外周T细胞淋巴瘤亚型：PTCL-GATA3和PTCL-TBX21, objectType=article, longId=185587, objectId=0f9018558e8f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9018558e8f, replyNumber=0, likeNumber=155, createdTime=2020-01-04, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9018558e8f, moduleTitle=Blood：两种新外周T细胞淋巴瘤亚型：PTCL-GATA3和PTCL-TBX21, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9018558e8f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312217, encodeId=c2f6131221ebe, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌, objectType=article, longId=183430, objectId=68dd183430c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68dd183430c6, replyNumber=0, likeNumber=90, createdTime=2019-11-24, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68dd183430c6, moduleTitle=国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68dd183430c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312216, encodeId=e8ed13122167f, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：如何识别外周T细胞淋巴瘤的亚型？, objectType=article, longId=180408, objectId=150d18040810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=150d18040810, replyNumber=0, likeNumber=90, createdTime=2019-10-04, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=150d18040810, moduleTitle=Blood：如何识别外周T细胞淋巴瘤的亚型？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=150d18040810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312215, encodeId=1a6e1312215ad, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤, objectType=article, longId=178703, objectId=280d1e870344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=280d1e870344, replyNumber=0, likeNumber=88, createdTime=2019-09-04, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=280d1e870344, moduleTitle=Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=280d1e870344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312214, encodeId=4d43131221402, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, objectType=article, longId=163986, objectId=5b4b163986c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4b163986c0, replyNumber=0, likeNumber=109, createdTime=2019-04-11, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4b163986c0, moduleTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4b163986c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312213, encodeId=eae0131221335, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤, objectType=article, longId=159564, objectId=19681595649e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19681595649e, replyNumber=0, likeNumber=60, createdTime=2019-02-08, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19681595649e, moduleTitle=2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19681595649e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312212, encodeId=7f121312212ff, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, objectType=article, longId=153842, objectId=37411538422c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37411538422c, replyNumber=0, likeNumber=85, createdTime=2018-11-20, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37411538422c, moduleTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37411538422c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312211, encodeId=ab4c131221171, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, objectType=article, longId=149700, objectId=ed23149e009d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed23149e009d, replyNumber=0, likeNumber=65, createdTime=2018-09-28, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed23149e009d, moduleTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed23149e009d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312210, encodeId=a64d1312210e6, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）, objectType=article, longId=148167, objectId=f37114816eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f37114816eaa, replyNumber=0, likeNumber=41, createdTime=2018-09-05, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f37114816eaa, moduleTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f37114816eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312209, encodeId=04f1131220962, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, objectType=article, longId=138647, objectId=e39113864ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39113864ec6, replyNumber=0, likeNumber=74, createdTime=2018-05-21, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39113864ec6, moduleTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39113864ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312208, encodeId=84a1131220854, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=73, createdTime=2018-03-09, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312207, encodeId=6a03131220ec4, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, objectType=article, longId=130749, objectId=b8ba130e490e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ba130e490e, replyNumber=0, likeNumber=81, createdTime=2018-02-28, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ba130e490e, moduleTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ba130e490e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

外周T细胞淋巴瘤

2020-05-29

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性

2021-12-04

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效

2021-11-09

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

科普贴：外周T细胞淋巴瘤（PTCL）

2021-08-08

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2021-07-14

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请

2021-07-04

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展

2020-11-28

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤

2020-11-26

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期

2020-07-31

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：两种新外周T细胞淋巴瘤亚型：PTCL-GATA3和PTCL-TBX21

2020-01-04

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌

2019-11-24

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：如何识别外周T细胞淋巴瘤的亚型？

2019-10-04

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：表观遗传修饰剂联合应用可有效治疗外周T细胞淋巴瘤

2019-09-04

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤

2019-04-11

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

2018 JSH实践指南：血液恶性肿瘤——外周T细胞淋巴瘤

2019-02-08

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤

2018-11-20

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定

2018-09-28

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）

2018-09-05

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！

2018-05-21

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-03-09

xlxchina (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤#

Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？

2018-02-28

科室
- - 订阅+
  - 更多科室
工具
服务